82例原发性肠道淋巴瘤临床特征与预后分析  

Clinical Features and Prognosis of 82 Cases of Primary Intestinal Lymphoma

作　　者：林筠 LIN Yun(Cadre Ward,Union Hospital Affiliated to Fujian Medical University,Fuzhou Fujian 350001,China)

机构地区：[1]福建医科大学附属协和医院干部病房,福建福州350001

出　　处：《中国卫生标准管理》2020年第20期89-91,共3页China Health Standard Management

摘　　要：目的评估原发性肠道淋巴瘤(PIL)的临床特点、治疗方法以及影响预后的相关因素。方法回顾性分析82例PIL患者临床资料,分为肠道B细胞淋巴瘤(IBCL)及T细胞淋巴瘤(ITCL),依据Lugano分期进行临床分期,行预后分析。结果68例(82.9%)为IBCL,14例(17.1%)为ITCL。多因素预后分析提示血清白蛋白水平正常、B细胞来源、LuganoI/II期及手术联合化疗,均为影响预后的独立因素。结论正常血清白蛋白水平、临床早期、IBCL、手术联合化疗的PIL患者预后更好。Objective To evaluate the clinical feature,treatment and prognostic factor of primary intestinal lymphoma(PIL).Methods The data of 82 patients with PIL were analyzed retrospectively and divided into intestinal B-cell lymphoma(IBCL)and T-cell lymphoma(ITCL).Results 68 cases(82.9%)were IBCL,14 cases(17.1%)were ITCL.Multivariate analysis indicated normal serum albumin,B-cell,lugano I/II stage and surgery combined with chemotherapy were independent prognostic factors.Conclusion The prognosis of patients with normal serum albumin,early stage,IBCL,surgery combined with chemotherapy is better.

关 键 词：原发性肠道淋巴瘤 肠道B细胞淋巴瘤 肠道T细胞淋巴瘤 Lugano分期 治疗方法 预后分析 

分 类 号：R733[医药卫生—肿瘤]